Abstract
Liver transplantation was approved for the treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for fulminant liver failure (also called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.
Current Drug Therapy
Title: Hepatitis B and Liver Transplantation
Volume: 4 Issue: 3
Author(s): Sandeep Mukherjee and Urmila Mukherjee
Affiliation:
Abstract: Liver transplantation was approved for the treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for fulminant liver failure (also called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.
Export Options
About this article
Cite this article as:
Mukherjee Sandeep and Mukherjee Urmila, Hepatitis B and Liver Transplantation, Current Drug Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157488509789054983
DOI https://dx.doi.org/10.2174/157488509789054983 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology A Review of Hypertension Management in Atrial Fibrillation
Current Hypertension Reviews Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
Current Vascular Pharmacology Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes
Mini-Reviews in Medicinal Chemistry Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design Serum Carotenoids and Risks of Diabetes and Diabetic Retinopathy in a Chinese Population Sample
Current Molecular Medicine Pancreatic Cancer: Promises and Failures of Target Therapies
Reviews on Recent Clinical Trials The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews Factor XII, Kininogen and Plasma Prekallikrein in Abnormal Pregnancies
Current Drug Targets Brainstem Neuropeptides and Vagal Protection of the Gastric Mucosal Against Injury: Role of Prostaglandins, Nitric Oxide and Calcitonin-Gene Related Peptide in Capsaicin Afferents
Current Medicinal Chemistry Nanomedicine for Intranasal Delivery to Improve Brain Uptake
Current Drug Delivery Editorial [Hot Topic: Drugs Targeted to Improve Endothelial Function: Clinical Correlates Between Sexual and Internal Medicine (Executive Editor: Antonio Aversa)]
Current Pharmaceutical Design Effects of Pulmonary Hypertension and Right Ventricular Function in Short and Long-Term Kidney Function
Current Cardiology Reviews Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Vitamin D: A Regulator of Metabolism and Inflammation
Current Nutrition & Food Science Editorial: Lipoprotein (a), More than Just Cholesterol?
Current Medicinal Chemistry Protective Effect of Natural Antioxidants on Heart Against Ischemia-Reperfusion Damage
Current Pharmaceutical Biotechnology Does the Acupoint Specificity Exist? Evidence from Functional Neuroimaging Studies
Current Medical Imaging